Co-formulation once-daily Insulin degludec/insulin aspart: One insulin for both initiation and intensification
Diabetes mellitus (DM) is a highly prevalent
disease,1 for which therapy has continually evolved over the years.
Currently, there are various non-insulin options available for managing
diabetes2; however, insulin remains one of the cornerstones of
therapy. The development of new insulin options offers many advantages in
achieving glycemic control but minimizing the risks of therapy, especially
hypoglycemia. In a Novo Nordisk-sponsored lunch symposium entitled “Leading the
Path in Diabetes Care: Insulin and Beyond” during the 20th Asian
Federation of Endocrine Societies (AFES) Congress on 21 November 2019 at the
Philippine International Convention Center, Dr Bien Matawaran discussed the
advantages and disadvantages of various insulin options, with emphasis on the
studies regarding the unique co-formulation once-daily 70% insulin degludec/30%
insulin aspart (IDegAsp).
